108. A novel bone graft has higher fusion rate than local autologous bone in stand-alone posterolateral fusion: a propensity score adjusted analysis
Daffner S, Bunch J, An H, Burton D, Milam R, Park D, Whang P, Strenge K. 108. A novel bone graft has higher fusion rate than local autologous bone in stand-alone posterolateral fusion: a propensity score adjusted analysis. The Spine Journal 2020, 20: s53-s54. DOI: 10.1016/j.spinee.2020.05.214.Peer-Reviewed Original ResearchLocal autologous boneOswestry Disability IndexPosterolateral fusionPatient outcomesBone graft substituteFusion rateLeg painAverage Oswestry Disability IndexMulticenter prospective cohort studyAutologous bonePropensity scoreSTUDY DESIGN/SETTINGSimilar patient outcomesProspective cohort studySF-36 PCSSF-36 MCSFlexion-extension radiographsRadiologic fusion rateNovel bone graft substituteDESIGN/SETTINGHigh fusion rateEndogenous growth factorsSF36-PCSDisability IndexBaseline characteristicsP122. Use of a novel allograft in single- and two-level posterolateral lumbar spinal fusion: two-year clinical and radiographic results from a prospective multicenter study
Daffner S, Bunch J, An H, Burton D, Milam R, Park D, Strenge K, Whang P. P122. Use of a novel allograft in single- and two-level posterolateral lumbar spinal fusion: two-year clinical and radiographic results from a prospective multicenter study. The Spine Journal 2020, 20: s204. DOI: 10.1016/j.spinee.2020.05.520.Peer-Reviewed Original ResearchIliac crest bone graftFusion rateBone graft substituteClinical outcomesSpinal fusionOswestry Disability Index scoresProspective multicenter cohort studyAutologous iliac crest bone graftSTUDY DESIGN/SETTINGIndependent core labPosterolateral lumbar spinal fusionSF-36v2 PCSDisability Index scoresMulticenter cohort studyPosterolateral lumbar fusion surgeryProspective multicenter studyBetter clinical outcomesLumbar fusion surgeryCrest bone graftGold standard graft materialLumbar spinal fusionDESIGN/SETTINGStandard graft materialPosterolateral spinal fusionEndogenous growth factors